Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab/cytotoxic chemotherapy treatment for metastatic colorectal cancer
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab/cytotoxic chemotherapy treatment for metastatic colorectal cancer |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Dolly A, Lecomte T, Bouche O, Borg C, Terrebonne E, Douillard J-Y, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas J-F, Servais S, Baracos VE |
Journal | CLINICAL NUTRITION |
Volume | 39 |
Pagination | 3319-3330 |
Date Published | NOV |
Type of Article | Article |
ISSN | 0261-5614 |
Mots-clés | Body composition, bone mineral density, Cancer, Chemotherapy, CT-scan, Skeletal muscle |
Résumé | Background: Changes in skeletal muscle mass (SMM), total adipose tissue mass (TAT) or bone mineral density (BMD) have been described in patients with cancer undergoing various treatments; simultaneous variations of all 3 tissues has not been reported. Methods: Data were prospectively collected in a clinical study (NCT00489697) including patients with liver metastases of colorectal cancer who received 4 cycles of bevacizumab in combination with cytotoxic chemotherapy. Computerized tomography (CT) at baseline and after chemotherapy was used to quantify skeletal muscle and adipose tissue cross-sectional areas, and mean lumbar spine BMD using validated approaches. Results: After exclusion of patients lacking adequate CT images or missing data, 72 subjects were included. Patients were 63% male, aged 63.2 +/- 10.3 years, 100% had liver metastases and 54%, 24% and 22% respectively has 0,1 and >= 2 extrahepatic metastases. 100% tolerated 4 cycles of treatment and none showed progressive disease at the end of treatment. The scan interval was 70 days (95% CI, 62.3 to 80.5). Thresholds for loss of tissue were defined as loss >= measurement error. 10% of patients showed no loss of any tissue and a further 43% lost one tissue (SMM, TAT or BMD); 47% of patients lost 2 tissues (16.5% lost SMM + TAT, 8% lost SMM + BMD, 10% lost TAT + BMD) or all 3 tissues (12.5%). Catabolic behavior (2 or 3 tissue loss vs 0 or 1 tissue loss) associated with disease burden, including unresectable primary tumor (p = 0.010), presence of extrahepatic (EH) metastases (p = 0.039) and number of EH metastases (p = 0.004). No association was found between the number of tissues lost and treatment response, which was uniformly high, or treatment toxicity, which was uniformly low. Conclusion: Multiple tissues can be measured in routine CT images and these show considerable inter-individual variation. Substantial losses in some individuals appear to associate with disease burden. (C) 2020 Published by Elsevier Ltd. |
DOI | 10.1016/j.clnu.2020.02.017 |